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Background: Penile prosthesis (PP) is a gold standard for treatment of erectile dysfunction given its
reliability and efficacy. Infection remains the most feared complication of prosthetic surgery, which usually
results in device removal, and places a significant economic burden on the healthcare system. While biofilms
have shown to support the persistence of microorganisms, the degree by which this matrix is truly pathogenic
remains unknown given its high prevalence even in asymptomatic patients. We aim to review and summarize
the current literature pertaining to biofilm formation in the setting of PP surgeries in clinically infected and
non-infected cases.
Methods: Searches were performed in the MEDLINE online database through PubMed using a
combination of keywords “penile prosthetic” OR “penile prosthesis” OR “penile implant” AND “biofilm”
OR “revision” OR “removal” OR “infection” OR “explant”. Eleven articles met inclusion criteria. There
were only three studies that explicitly listed the number of biofilms identified in their cohort, but we also
included eight articles that mentioned swabbing and culturing of any bacterial biofilm during revision
procedures for both clinically infected and non-infected implants.
Results: Infected PP yielded a 11–100% rate of biofilm presence, while non-infected PP yielded a 3–70%
rate of biofilm presence. Time to reoperation from initial PP placement were also largely variable, ranging
from 2 weeks to over 2 years. Coagulase-negative staphylococcus (i.e., Staphylococcus epidermidis) were the
most commonly reported organisms among non-infected implants, however, newer studies have identified a
change towards more virulent organisms.
Conclusions: Since the advent of PP surgery, diabetes control, revision washout protocols and antibioticimpregnated devices have led to an overall decrease in biofilm formation and infectious complications.
There is an overall paradigm shift in microbial profiles with more virulent organisms, such as Escherichia
coli, Pseudomonas aeruginosa, Enterococcus species, and even fungal species beginning to replace the more
common coagulase-negative staphylococcal species, especially in clinically infected implants. Additional
studies are necessary to define the significance of bacterial presence in biofilms using impactful technologies
such as next-generation sequencing. Currently, preliminary and experimental biofilm-control strategies are
also underway to further address this clinical issue.
Keywords: Penile prosthesis (PP); biofilm; infection; antibiotic
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Introduction
Due to its long-term durability and high rates of patient
and partner satisfaction, penile prosthesis (PP) implantation
is now regarded as a gold standard treatment for medically
refractory erectile dysfunction (ED) (1,2). According to
the American Urological Association guidelines, PP can
be considered as a first-line treatment option for ED,
which differs from the previously recommended stepwise
approach (3). Recent reviews have suggested that PP
implantations may not only be the most effective treatment
for ED, but also the most cost effective compared to other
medical therapies in specific populations, such as those
after ischemic priapism (4-6). With the growing body of
literature surrounding the efficacy of PP for ED, device
failure rates and surgical complications have also been
well established. Of these, infection remains the most
concerning sequelae, often necessitating device removal and
subsequent revision surgery with suboptimal outcomes (7).
Device infections are thought to be caused by the
introduction of microorganisms via incisions at the time
of surgery or via hematogenous spread. Typically, the
host defense mechanisms and prophylactic antibiotics kill
the bacteria; however, in the setting of medical device
implantation into a surgical wound, the implant is rapidly
coated with serum proteins and ultimately the body deems
it as a foreign body and coats it with a conditioning layer of
fibrous capsule, which can alter the surface characteristics of
the inanimate object (8). This serum-coated surface is ideal
for bacterial adherence and subsequent biofilm formation
(Figure 1). Bacterial biofilms are communities of adherent
bacteria protected against the body’s immune system and
antibiotics by a protein-containing polysaccharide matrix.
During this process, the cells undergo phenotypic changes
that render them less metabolically active and, therefore,
more drug resistant (9). The risk of device infection is
further increased after revision surgery due to weakened
host-resistance factors, impaired wound healing related to
scar formation and, most importantly, decreased antibiotic
penetration secondary to bacterial biofilm formation (10).
Bacterial biofilms are problematic to the prosthetic
surgeon and catastrophic for the patient as they are
extremely difficult to prevent or treat. Within the urologic
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field, biofilms can cause complications with simple devices
such as urethral catheters or indwelling ureteral stents, as
well as PP implants. An understanding of these biofilms
and the microbes they harbor is essential to understanding
the pathophysiology of device infection and malfunction.
Herein, we aim to provide the readership with a scoping
review of the current literature pertaining to biofilm
formation in the setting of PP surgeries. We present the
following article in accordance with the PRISMA-ScR
reporting checklist (available at https://tau.amegroups.com/
article/view/10.21037/tau-22-195/rc).
Methods
A literature review of articles indexed in the MEDLINE
online database was performed through PubMed from
January 2022 to February 2022. Keyword searches
including a combination of the terms “penile prosthetic”
OR “penile prosthesis” OR “penile implant” AND “biofilm”
OR “revision” OR “removal” OR “infection” OR “explant”
were utilized to identify appropriate articles to include in
our review in accordance with the PRISMA Extension for
Scoping Reviews protocol (11). Only original articles that
were peer-reviewed and published in English were included.
There was no limit placed on publication year. Article types
including editorial comments, review articles or systematic
reviews and meta-analysis were excluded. Articles spanned
from 1953 to 2022. Titles, abstracts, and full texts were
reviewed for inclusion based on appropriateness by three
authors (JYL, CEC, MJD) independently. Articles were
only included if they specifically identified or cultured
biofilm during PP revision surgeries. Variables including
presence of biofilm, microbial data (number of isolates,
number of species, organism type), time to reoperation,
culture sensitivities and administered antibiotics were
abstracted. Upon identifying and screening the 160 eligible
articles, a total of 11 articles that met inclusion criteria
were found (Figure 2). We included an early case report
that first described and identified biofilm in two patients
with infected PP implants. We qualitatively analyzed and
summarized the data from these articles and descriptively
presented them in Table 1.

Transl Androl Urol 2022;11(8):1210-1221 | https://dx.doi.org/10.21037/tau-22-195

Leong et al. A scoping review of penile implant biofilms

1212

B

A

×2.5K

×500

30 μm

200 μm

Figure 1 Implant surfaces from devices explanted for mechanical malfunction, preserved with formalin, dried, gold sputter-coated and
visualized by scanning electron microscope, (A) pump, (B) cylinder. (A) Surface features and apparent bacterial biofilms sequestered in an
implant crevice; surface irregularities are favored for bacterial attachment. (B) Surface texture and extensive cellular colonization among

Identification

biological debris, morphology is consistent with white cells.

Records identified through PubMed MEDLINE
database searching “penile prosthetic” OR
“penile prosthesis” OR “penile implant” AND
“biofilm” OR “revision” OR “removal” OR
“infection” OR “explant”
(n=3,171)

Screening

Duplicates removed (n=2,204)
Records screened after duplicates removed
(n=967)

Full-text articles assessed for eligibility
(n=160)

Records excluded (n=807)
• Review articles/systematic reviews/
animal studies/basic science studies/
non-English

Eligibility

Full-text articles excluded (n=149)
• Unrelated sites/topics
• Does not examine the role of biofilm

Included

Studies included in scoping review
(n=11)

Studies specifically mentioning
number of implants with biofilm
identified (n=3)

Studies mentioning
swabbing/culturing biofilm if it was
present (n=8)

Figure 2 PRISMA-ScR flowchart of database search.

Results

for both clinically infected and non-infected implants.

While there were only three studies that explicitly listed
the number of biofilms identified in their cohort, we also
included eight others that mentioned the swabbing and
culturing of any bacterial biofilm during revision procedures
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These results are summarized in Table 1.
The first study describing biofilms on PP was published
by Nickel et al. in 1986 whereby two patients with clinically
infected PP harbored rod and coccoid shaped bacterial
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Table 1 Presence of biofilm on penile prosthesis implants during revision surgery
First
author,
year

Percentage of
biofilm present

Microbial data
Number of Number of
Organism type
isolates
species

Chung,
2022*

48/83 (56%) on
next-generation
sequencing;
24/83 (29%) on
standard culture

–

21

Gross,
2020*

71%

–

Gross,
2019*

26/26 (100%)
infected implants
(fungal)

Jani,
2018*

Time to
reoperation,
median (range)

Culture sensitivities Perioperative antibiotics

Infected: P. aeruginosa
(50%); Erosion: S.
epidermidis (75%);
Mechanical malfunction:
E. coli (72%)

28 months
(interquartile
range
43.5 months)

–

Gram-positive bacteria
(44%), Gram-negative
bacteria (25%)

2 months (2–
–
81 months); mean
5.4 months

–

26

5

Candida sp. (97%), C.
albicans (62%)

4.8 months
(12–120 months)

In addition to standard
perioperative antibiotics,
no patients received
antifungals at initial
implantation, 15%
received antifungals
before explant, 31%
received antifungals
during explant

130/236 (55%)

127

27

Staphylococcal sp. (77%), Mean 56 months
S. epidermidis (43%)
(standard
deviation
51 months)

All isolates sensitive –
to tetracycline/
rifampin

Gross,
2017*

153/227 (67%)
infected implants

204

35

E. coli (18%), Coagulase- 1.5 months
negative Staphylococcal (0.5–81 months);
sp. (15%), Candida sp.
mean 4.8 months
(11%)

Vancomycin +
gentamicin OR
vancomycin +
aztreonam (86%
efficacy)

Implantation: 56%
vancomycin/gentamicin,
22% ancef/gentamicin;
Salvage/explant: 50%
vancomycin/gentamicin,
15% ancef/gentamicin

Ciftci,
2016

2/71 (3%) noninfected implants;
2/18 (11%)
positive culture

5

21

S. epidermidis (57%),
2/2 biofilms cultured
S. epidermidis

41 months (8–
82 months)

–

–

Kava,
2011*

5/51 (10%)

7

6

S. epidermidis (29%)

9.6 months (6–
138 months)

–

–

Henry,
2008*

97/148 (66%)
non-infected
implants

124

20

Staphylococcal sp.
(87%), S. epidermidis
(44%)

Mean 47.9 months –
(range 1–
190 months)

–

–

–

Gram-positive cocci
(80%), Gram-negative
rods (70%), Yeast (60%)

>2 years

–

–

Silverstein, 7/10 (70%) non2006
infected implants;
7/8 (88%) positive
culture

Vancomycin +
gentamicin with
broadest coverage

–

–

Henry,
2004*

54/77 (70%) noninfected implants

64

15

Staphylococcal sp.
(81%), S. epidermidis
(39%)

Mean 53 months
(range 2–
190 months)

All Staphylococcal –
sp. isolates sensitive
to tetracycline/
rifampin

Nickel,
1986

2/2 (100%)
infected implants

–

–

Coccoid bacterial cells
(100%), P. aeruginosa
(50%)

1 month; 2 years

–

Cefalexin; trimethoprimsulfamethoxazole

*, Studies did not explicitly mention the number of biofilms identified, but noted that bacterial biofilm was swabbed and cultured if
observed during salvage procedure.
© Translational Andrology and Urology. All rights reserved.
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cells (12). These patients were successfully treated with
oral antibiotics. The next study by Silverstein et al. found a
70% rate of biofilm formation among non-infected, nonantibiotic coated implants, 88% of which did have positive
cultures (13). Most recently in 2016, Ciftci et al. identified
biofilm in 11% of implants removed for non-infectious
reasons, all of which grew Staphylococcus epidermidis (14).
Next, we also noted that for non-infected implants or
implants removed secondary to mechanical malfunction,
the most common reported organisms were coagulasenegative staphylococcus (i.e., S. epidermidis), which ranged
from 15–81% in our cohort. Conversely, implants removed
for infection harbored other organisms such as P. aeruginosa
in 50% of one reported cohort or E. coli in 18% of another
cohort.
The percentage of biofilm presence were based on
whether the PP were clinically infected or not. When PP
were infected, the rate of biofilm presence ranged from 11–
100%, while biofilm presence ranged from 3–70% in noninfected PP. Time to reoperation from initial PP placement
were also largely variable, ranging from 2 weeks to over
2 years.
Discussion
What is biofilm?
Historically, biofilm is defined as “a structured consortium
of bacteria encased in a self-producing matrix that exhibits
a unique pattern of gene expression and growth” and is
almost always associated with a surface for attachment
(15-17). Its structure can be divided into three layers—a
deep, linking layer abutting the adherent surface, a compact
base layer of bacteria, and a superficial surface film on which
free-floating bacteria can arise and spread (18).
Biofilm formation can be distilled down to four phases—
attachment, aggregation, maturation and detachment (19).
The first stage is arguably the most important step, and
involves foundational forces and biological proteins from
planktonic bacteria that establish interactions to adhere to
the inanimate substratum (15,18). The second stage involves
accumulation, growth and development of cell layers on the
surface. During the third maturation phase, the insoluble
three-dimensional matrix or extracellular polymeric
substance (EPS) is formed. This “film” encases the microbes
and serves as a channel for bulk fluids to flow and permits
the distribution of chemical signals and nutrients (20).
Lastly, as the colonies grow, quorum sensing occurs
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triggering expression of cleavage enzymes that subsequently
release bacteria from the colonies resulting in the last step,
detachment and dispersion (21). These bacteria are now
free to seed other locations within the host and begin the
cycle anew (22,23).
The challenges of biofilm
Biofilm can be particularly problematic to prosthetic
surgeons and patients as they are not only resistant to most
traditional treatments but are also difficult to prevent.
Most antibiotic strategies, such as identifying the minimum
inhibitory concentration of an antibiotic to determine the
appropriate amount of drug for a specific strain of bacteria,
are designed for planktonic bacteria and may be insufficient
for adherent bacteria, sometimes by several orders of
magnitude (24). While current antibiotics were designed
to eradicate planktonic bacteria, biofilm colonies are not so
easily studied as they are difficult to reproduce by standard
methods (16,22). These infections also tend to resist innate
and adaptive immune responses as well as antimicrobial
agents due to their thick extracellular matrix that serves
as a barrier to impede the penetration of antibiotics (25).
Moreover, antibiotics that do reach the microbe biomass
layer may be rendered less effective due to their reduced
metabolism and sub-therapeutic concentrations. Finally,
biofilms are slow growing to the point of dormancy, and
these “persister cells” have the ability to remain viable even
after treatment with very high doses of antibiotics (26).
With regards to PP implants, the formation of a fibrous
capsule represents another hurdle for antibiotic treatment
and penetration of infected implants. These capsules
are typically avascular, which further results in reduced
antibiotic delivery to the intended area of treatment (27).
With reduced drug delivery, there is decreased distribution
of chemotactic signals, e.g., cytokines that are necessary to
induce an inflammatory response or stimulate neutrophils
to reach microbes deep within the biofilm colonies (15).
Biofilms may possibly play a role in the spread of
antimicrobial resistance through the horizontal transfer
of resistance and virulence genes when in close proximity
within the extracellular biofilm matrix (28). Exposure to
subtherapeutic concentrations of antibiotics allows for
selection pressures and the potential for development
of resistant or virulent strains of bacteria. Together, the
challenges in treating biofilms associated with prostheticassociated infections emphasize the importance of prosthesis
removal in most cases.
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Biofilms in penile prostheses
Biofilm development is widely accepted as a pathologic
step in PP infections, and their tolerance or resistance to
traditional antimicrobial regimens heightens their clinical
importance. Prosthetic surgeons have attempted to use
standard culture results to tailor antibiotic therapy for
revision patients. Nonetheless, multi-institutional data
evaluating clinically infected PP explants have documented
non-specific or even no growth cultures in up to 33%
of cases (29). This may be secondary to flaws in culture
collection techniques, the administration of antibiotics
prior to culture collection, or the challenges in growing and
identifying all biofilm-associated microbes (8).
With the advent of infection-retardant coatings and
revision washout protocols, current literature documents
a decrease in infection rates from 2–4% to less than
2% in primary implants, and from 7–18% to 2–3% in
revision cases (10,30-35). Moreover, recent systematic
reviews report a change in the microbial composition in
clinically uninfected and infected PP over time (29). The
abundance of coagulase-negative staphylococcal species,
most commonly S. epidermidis, have shown a decreased
proportion in cultures for explanted PP. Other species such
as E. coli, P. aeruginosa, Enterococcus species, and even fungi
that form biofilms have been on the rise (29,36).
Table 1 summarizes the review of the presence of
biofilm identified on PP revision surgery for both clinically
infected and non-infected implants. While there were only
three studies that explicitly listed the number of biofilms
identified in their cohort, we also included several others
that mentioned swabbing and culturing of any bacterial
biofilm during revision procedures. In 1986, Nickel et al.
described one of the first instances of biofilm presence
in two patients with clinically infected PP, both of which
harbored rod-shaped and coccoid bacterial cells (12).
Subsequently in 2006, Silverstein et al. described the
presence of bacteria on laser microscopy among eight of
ten non-antibiotic coated-PP explanted for mechanical
function, seven of which had biofilm (13). Ciftci et al. also
specifically identified biofilm in two of 18 non-infected
implants who had a positive culture; both of these biofilms
grew S. epidermidis (14). Most recently, Chung et al. also
identified biofilm on both standard culture and nextgeneration sequencing (NGS) in 24 and 48 of 83 samples,
respectively (36). Interestingly, this pilot study was the first
to assess the utility of NGS in the detection of biofilm and
was not only able to detect microbes better than traditional

© Translational Andrology and Urology. All rights reserved.

1215

culture, but also detected different microbial profiles for
PP explanted for different surgical indications. This may
help guide the selection of peri-operative antibiotics and
PP-coated antibiotics or hydrophilic dips for individualized
scenarios.
Based on historic trends, in revision cases performed for
clinically uninfected cases, most cultures from explanted
PP are positive for S. epidermidis, a part of common skin
flora. Even in the setting of infected PP, the reported
presentations are typically with lower toxicity and are
confined to the implant space. These bacteria are likely
introduced during primary implantation and once they
form their mucinous biofilm, they appear able to live in the
PP environment without always causing clinical signs of
infection (10,27). During revision or salvage procedures,
the disruption of pre-existing biofilms and dissemination
of these bacteria are thought to contribute to the higher
infection rates (37).
In recent articles assessing antibiotic-coated implants,
the prevalence of Staphylococcal cultures seems to have
decreased, with a slow rise in the incidence of more toxic
organisms such as E. coli, P. aeruginosa, Enterococcus species,
and even fungal species, such as C. albicans. The recent
multi-centered study by Gross et al. assessing cultures in
227 infected implants undergoing revisions found that E.
coli was the most common isolate (18%), coagulase-negative
staphylococcus was the second (15%), and Candida species
isolates were the third most common (11%) (29,38). Even
more recently, a study using NGS found that P. aeruginosa
and E. coli were the most frequent and abundant organisms
encountered in their cohort of infected and mechanically
malfunctioned patients, respectively (36). Some reports
have also demonstrated a discrepancy in the culture data
between the first revision surgery for non-infectious reasons
when compared to the second revision for infectious
etiologies (14). Of 202 revision surgeries for infection
reported by Chandrapal et al., they found that only 22%
of implants grew the same organisms at explantation for
infection when compared to their original swabs at first
revision (39).
Current applications to reduce biofilm attachment
Advances in PP designs with the use of infection-retardant
coatings have also led to significant decreases in overall
PP infection rates (40). Boston Scientific (Marlborough,
MA) introduced the InhibiZone technology into the AMS
700 inflatable PP in 2001, which contains minocycline
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and rifampin (41). Devices were impregnated with this
combination due to the low incidence of allergies and the
efficacy of these antibiotics against Gram positive and
negative bacteria commonly seen in PP infections (41).
The Coloplast (Minneapolis, MN) Titan inflatable
PP comes with a hydrophilic coating in 2002, known
as polyvinylpyrrolidone, which absorbs an antibiotic
when dipped into an aqueous solution, giving prosthetic
surgeons more flexibility when tailoring their antibiotic
of choice (42,43). While the ideal antibiotic solution and
“dipping time” have yet to be described, a combination
of vancomycin and gentamicin mixed in normal saline
solution is typically the antibiotics of choice unless
clinically contraindicated due to its broad coverage against
most Gram positive and negative microbes. Due to its
convenience and efficacy, some authors have also studied
the utility of Irrisept (Irrimax Corporation, Lawrenceville,
GA), a low-concentration 0.05% chlorhexidine gluconate
solution that has broad spectrum antibacterial, antifungal,
and antiviral properties as a dipping solution (44). They
found satisfactory coating results on Coloplast Titan PP
when compared to saline soaked controls. Furthermore,
they found no difference in coating adherence between
soaking times of 1, 15, 30 and 60 minutes. The introduction
of antibiotic-coated PP has also been shown to improve
infection-free survival in diabetic cohorts (45). A systematic
review and meta-analysis of 14 clinical case studies found
the rates of infectious complications to be significantly lower
in the cohort with antibiotic coated prostheses at 0.89%
when compared to those without (2.32%; P<0.01) (46).
A recent study performed by Jani et al. also found higher
rates of culture positive isolates in uncoated PP regardless
of whether explant surgery was performed for infectious
or non-infectious etiologies (47). Overall, the utility
of antibiotic coatings confers significant advantages in
preventing postoperative device infections (48,49).
The use of antibiotic washout during revision surgery
is also a critical step that has been shown to significantly
reduce infection rates. Mulcahy et al. first revolutionized
the management of infected PP by assessing the feasibility
of immediate replacement of inflatable PP at the time of
revision surgery after a seven-step antibiotic irrigation
protocol (50). Prior to the introduction of the salvage
technique, treatment of PP infection involved the removal
of all prosthetic components along with copious antibiotic
irrigation to the PP site (51). This often resulted in fibrosis
and scarring of the corpora cavernosa, complicating
subsequent reimplantation in the future. Since the
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development of the Mulcahy protocol in 1996, other
groups have demonstrated promising results with the use
of the immediate salvage technique and also modified their
techniques with a delayed or malleable salvage method
with other antibiotic irrigation solutions (52-56). For
example, cohorts from Wilson and Henry both reported a
reduction of infection rate from 10% to 3% in the cohort
who underwent antiseptic washout after revision surgery
(27,33). Importantly, while antibiotic coatings on PP have
demonstrated desirable outcomes in primary surgeries, its
effects on revision cases are less pronounced, and studies
have noted decreased rates of infection in revision surgeries
only if adjunctive revision washout was performed (33,57).
This indicates that while antibiotic coatings can prevent
infections secondary to planktonic bacteria during initial
implantations, once biofilms are established, a more
rigorous irrigation and lavage is necessary to eliminate latent
microbes and disrupt biofilms in previous implant spaces (10).
Hence, revision washout is recommended even in patients
who undergo revision for non-infectious indications (27).
A report by Abouassaly et al. also commented that revision
washouts should be aggressive, with the use of copious
amounts of one type of antimicrobial solution rather than
smaller amounts of several antibiotics (58). Occasionally,
mechanical debridement of biofilm in the implant space may
also be necessary.
Patients with prior PP who are undergoing revision
surgeries are also considered high risk for infection, likely
for reasons related to biofilm formation as mentioned
previously. Traditionally, revision surgeries have a
10–13% rate of infection, a significantly higher percentage
when compared to primary cases at <3% (32,33). Another
study demonstrated that risk of device infection strongly
correlated with an increased number of implantations with
6.8% risk for the primary implantation compared to 100%
by the fifth implantation (59). Finally, the consequence of
device infection is multifactorial; hence, careful patient
selection, paired with the advent of recent technological
innovations is essential to ameliorate the risk of this
complication.
Future of biofilm prevention and treatment
While there are many novel possibilities for the prevention
and treatment of bacterial biofilms, the majority of
these methods are still in the experimental phase and
are still being studied in vitro. Given the surgical volume
in orthopedics and neurosurgery, most innovative
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biomaterial strategies are focused on these implants, but the
advancements can be translated to the urologic prosthetic
realm (9). The primary strategy to prevent biofilm
formation and subsequent device infections is to prevent
bacterial attachment altogether. Surface modification
or impregnated antibiotic are methods that can render
biologic surfaces inhospitable to microbes. Both the Boston
Scientific and Coloplast inflatable PP are coated implants,
but only the Coloplast malleable PP is coated with a
hydrophilic layer to create a physical barrier to prevent
microbial attachment (23). A new inflatable and malleable
PP from Rigicon (Ronkonkoma, NY) also supports a
hydrophilic layer (60). Changes in hydrophobicity as a
result of altering the electrical charges of a surface can also
prevent certain proteins from binding to solid surfaces.
For example, the application of heparin coating has been
used on intraocular lenses and urethral catheters to reduce
bacterial adhesion (61-63). The addition of morphologic
barriers such as antimicrobial peptides have also been
utilized in the orthopedic field (64-68). However, these
peptides have shorter duration of action which may pose a
limitation for its use in PP. Other antimicrobials that have
been tested for prosthetic coating include chlorhexidine,
nitric oxide and triclosan, but have not been used in PP (69).
Also, biologic approaches such as the use of commensal
bacteria to prevent the colonization of pathogenic bacteria
may play a protective role in the adhesion and proliferation
of pathologic bacteria. The use of biosurfactant produced
by these probacteria to inhibit attachment of other virulent
strains of bacteria in clinical practice is still unclear (70,71).
Aside from targeting adhesion, the first phase of biofilm
formation, studies have attempted to inhibit microcolony
formation by disrupting the EPS. The formation of EPS
allows for cell-to-cell communication between microbes
that aid in the development of resistance through clonal
gene expression changes and can also act as a diffusion
barrier for antibiotics (23). One method to destabilize the
EPS include enzymatic disruption of fibrin deposits that
act as the central structural unit of biofilms with the use of
tissue plasminogen activator. Mechanical disruption using
microbubble-based, contrast enhanced, ultrasound imaging
creates cavitations that disrupt the biologic fluid and tissue
membrane interfaces of biofilm (72). It can delineate
anatomy intraoperatively, allow for targeted drug delivery
and facilitate gene therapy through alterations in cell
membrane permeability, as seen in hepatobiliary anatomy
(73-77). In 2015, an in vivo study by Li et al. evaluated the
effects of ultrasound-targeted microbubble destruction

in combination with a cationic antimicrobial peptide,
human β-defensin 3 on antibiotic-resistant Staphylococcus
biofilms (78). Their findings suggest that the combination
of ultrasound use significantly decreased the biofilm
densities, percentage of live cells, and viable counts of
tested Staphylococcus colony forming units. The degree
of mechanical insult induced by acoustic rupture of these
microbubbles depends largely on biofilm age and thickness.
Future work is necessary to determine if this modality will
be a safe and efficacious method in preventing or treating
PP biofilms.
Experimental studies evaluating dispersion-inducing
agents that coax microbes to shed their protective biofilm
coating may be an important proof-of-concept that can
aid in biofilm control. Studies in S. aureus species have
shown that active quorum-sensing prevents the formation
of biofilm (79). The disruption of the accessory gene
regulator (agr) gene function, which mediates the quorumsensing mechanism, may theoretically represent a method
to induce biofilm dispersion (79,80). In Pseudomonas species,
alterations in genetic regulation of intracellular signal
transducers e.g., Lipopolysaccharide assembly protein A
(LapA) proteins, and activation of EPS enzymes e.g., LapG
proteinase, represents mechanisms to promote dispersion of
established biofilms as well (81,82).
Recently, emerging technologies have allowed for
more sensitive and superior testing, one of which is the
advancement of rapid molecular sequencing. Our group
recently performed a study assessing the utility of a novel
technology, NGS, for the identification of microorganism
profiles on explanted biofilms (36). We found that NGS was
able to detect microbes more abundantly and frequently
when compared to standard culture and that the microbial
profiles differed based on etiologies for revision surgery,
including infection, erosion, or mechanical malfunction.
We also found that NGS tended to detect a polymicrobial
profile, while culture results were only monomicrobial.
Although the significance of the polymicrobial findings
detected by NGS have yet to be ascertained, these findings
may guide surgeons in the selection of perioperative
antibiotics and hydrophilic antibiotic dips in individualized
clinical scenarios for the treatment of biofilms (36,83).
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Limitations
There are some limitations to our scoping review process.
While it entails a different screening criteria or process than
a systematic review, it is a broader and less refined search.
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It also requires multiple search strategies and increases
the emphasis for hand searching within individual articles.
Hence, it requires a larger team for screening larger
volumes of literature which may lead to inconsistencies in
interpreting and conducting these reviews. There is also a
possibility that we may have missed some relevant studies
due to database selection or inclusion of only articles
published in English. Depth of analysis may be limited by
time constraints as well to review all articles. Lastly, the lack
of critical appraisal of included studies is also a limitation.
It cannot be used to endorse guideline recommendations as
it did not assess the quality of included studies and is also
limited to identifying gaps in the literature related to low
quality research.
Conclusions
PP remains the gold standard for treatment of ED given
its reliability and efficacy. Infection remains the most
feared complication of prosthetic surgery, which usually
results in device removal. While biofilms are believed to
be the culprit, the degree to which this bacterial matrix
is truly pathogenic remains unknown—especially given
its high prevalence even in asymptomatic patients. What
has been noticed is that in the era of antibiotic-coated
implants, less common, but more virulent organisms are
beginning to replace the more common Staphylococcal
species in clinically infected implants. These patients
also present with more toxic, systemic infections and
ultimately require device removal altogether for source
control. While revision washout protocols and antibioticcoated implants have decreased overall infection rates,
testing of preliminary and experimental biofilm-control
strategies is necessary to further address this clinical issue.
Moreover, additional studies including a prospective,
randomized controlled trial is currently underway to define
the significance of bacterial presence in biofilms using
innovative technology such as NGS.
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